Compare DexCom, Inc. (DXCM) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Wipro Limited — how do they compare? DexCom, Inc. trades at $77.95 (market cap $28.06B), while Wipro Limited trades at $1.85 (market cap $18.31B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Wipro Limited pays a 10.42% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | WIT | |
|---|---|---|
Market Cap | $28.06B | $18.31B |
Sector | Health | Technology |
52-Week High | $89.53 | $3.06 |
52-Week Low | $54.84 | $1.82 |
Enterprise Value | $27.03B | $14.69B |
Dividend Yield | — | 10.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
WIT trades at $1.82, down 1.09% on the day, with a bearish technical signal from moving averages and oscillators. The company reported a net income of $131.35 billion for 2025 with a 14.25% margin, though recent quarters show earnings misses. Revenue guidance remains cautious amid client spending constraints, while strategic AI partnerships aim to drive future growth.
The outlook is mixed: valuation ratios appear reasonable with a P/E of 13.82, but weak near-term revenue visibility and consecutive earnings misses pose risks. Analyst sentiment is cautious with only 19% buy ratings. Upside depends on AI initiatives translating to sustained growth, while downside risks include sector-wide demand pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
